Abstract
Patients with moderate-to-severe psoriasis, will require phototherapy, systemic therapy, or both for adequate disease control. Although a number of well established therapies are available for psoriasis, there are still unmet needs remain, such as longterm safety and practicability. Psoriasis currently regarded as an immune-mediated inflammatory disease, inflammatory response is amplified as a result of increased tumor necrosis factor (TNF) α expression in psoriatic plaques. New biological agents targeting TNFα are promising in psoriasis therapy. Adalimumab is an fully human recombinant IgG 1 monoclonal antibody specific for human TNF α that has been approved for the treatment of rheumatoid arthritis. Adalimumab has only recently been introduced to dermatology. Given the known pathophysiologic role of TNF in psoriasis, this brief review aimed to evaluate the efficacy and safety of adalimumab in the treatment of psoriasis and other dermatoses which it found off-label uses.
Keywords: Adalimumab, psoriasis, biological agents
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Title: Adalimumab
Volume: 6 Issue: 3
Author(s): Meltem Uslu
Affiliation:
Keywords: Adalimumab, psoriasis, biological agents
Abstract: Patients with moderate-to-severe psoriasis, will require phototherapy, systemic therapy, or both for adequate disease control. Although a number of well established therapies are available for psoriasis, there are still unmet needs remain, such as longterm safety and practicability. Psoriasis currently regarded as an immune-mediated inflammatory disease, inflammatory response is amplified as a result of increased tumor necrosis factor (TNF) α expression in psoriatic plaques. New biological agents targeting TNFα are promising in psoriasis therapy. Adalimumab is an fully human recombinant IgG 1 monoclonal antibody specific for human TNF α that has been approved for the treatment of rheumatoid arthritis. Adalimumab has only recently been introduced to dermatology. Given the known pathophysiologic role of TNF in psoriasis, this brief review aimed to evaluate the efficacy and safety of adalimumab in the treatment of psoriasis and other dermatoses which it found off-label uses.
Export Options
About this article
Cite this article as:
Meltem Uslu , Adalimumab, Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry 2007; 6 (3) . https://dx.doi.org/10.2174/187152307781368210
DOI https://dx.doi.org/10.2174/187152307781368210 |
Print ISSN 1871-5230 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-614X |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Emerging Roles of MicroRNA-22 in Human Disease and Normal Physiology
Current Molecular Medicine Airway Clearance of Apoptotic Cells in COPD
Current Drug Targets The IL23/Th17 Pathway as a Therapeutic Target in Chronic Inflammatory Diseases
Inflammation & Allergy - Drug Targets (Discontinued) C-Reactive Protein: Interaction with the Vascular Endothelium and Possible Role in Human Atherosclerosis
Current Pharmaceutical Design Liposomes: Targeted and Controlled Delivery System
Drug Delivery Letters Involvement of the P2X7 Purinergic Receptor in Inflammation: An Update of Antagonists Series Since 2009 and their Promising Therapeutic Potential
Current Medicinal Chemistry Pharmacological Influencing of The Cholinergic Anti-inflammatory Pathway in Infectious Diseases and Inflammatory Pathologies
Mini-Reviews in Medicinal Chemistry Synthesis and Pharmacological Effects of the Anti-Cancer Agent 2-Methoxyestradiol
Current Pharmaceutical Design Association of Autoimmune Disorders and Disease-modifying Antirheumatic Drugs: (DMARDs) with the Risk of Alzheimer’s and/or Dementia: A Population Study Using Medicare Beneficiary Data
Current Alzheimer Research Apolipoprotein E Gene Variants of Alzheimer's Disease and Vascular Dementia Patients in a Community Population of Nanking
Medicinal Chemistry Biologic Drugs for Analgesia: Redefining the Opportunity
Current Pharmaceutical Biotechnology Targeting Interleukin (IL) 5 for Asthma and Hypereosinophilic Diseases
Recent Patents on Inflammation & Allergy Drug Discovery Pain Perception and Management: Where do We Stand?
Current Molecular Pharmacology Renal Cell Carcinoma in a Patient with Rheumatoid Arthritis Treated with Adalimumab
Current Drug Safety Role of Resistin in Insulin Sensitivity in Rodents and Humans
Current Protein & Peptide Science Chinese Medicine: A Novel Therapeutic Option for Pancreatic Cancer
Current Signal Transduction Therapy Antisynthetase Syndrome: A Review of Etiopathogenesis, Diagnosis and Management
Current Medicinal Chemistry Recent Progress of Small Molecular VEGFR Inhibitors as Anticancer Agents
Mini-Reviews in Medicinal Chemistry MAPKs as Mediators of Cell Fate Determination: an Approach to Neurodegenerative Diseases
Current Medicinal Chemistry The Therapeutic Potential of Adenosine Triphosphate as an Immune Modulator in the Treatment of HIV/AIDS: A Combination Approach with HAART
Current HIV Research